CARMINE DE ANGELIS

Assistant Professor

University of Naples Federico II

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Carmine De Angelis is an Assistant Professor at the University of Naples "Federico II" in Italy. His research primarily focuses on breast cancer, investigating topics such as immune checkpoint inhibitors, resistance to endocrine therapy, and the role of molecular classifiers in predicting treatment responses. Recent articles highlight his contributions to understanding gender disparities in clinical trials and the implications of novel therapies in advanced breast cancer treatment.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (8)

Fabio Puglisi

Head of the Unit of Medical Oncology and Cancer Prevention

ITALY

View details

Zhao Zhang

Assistant Professor

University of Texas Health Science Center at San Antonio

UNITED STATES

View details

Xiaoyong Fu

Assistant Professor

Baylor College of Medicine

UNITED STATES

View details

Fabiana Napolitano

University of Naples Federico II

ITALY

View details

Carolina Gutierrez

Professor

UNITED STATES

View details

Jamunarani Veeraraghavan

Assistant Professor

Baylor College of Medicine

UNITED STATES

View details

Luigi Formisano

Università Federico II

ITALY

View details

Meghana V Trivedi

Associate Professor

University of Houston

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

CARMINE DE ANGELIS

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review

Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)

Prognostic implications of risk definitions from the monarchE and NATALEE trials

Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study

EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer

Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients

A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer

A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer

Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

Erratum: Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer (Clinical Cancer Research (2021) 27 (4870-4882) DOI: 10.1158/1078-0432.CCR-19-4191)

Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.

Collaborators (8)

Fabio Puglisi

Zhao Zhang

Xiaoyong Fu

Fabiana Napolitano

Carolina Gutierrez

Jamunarani Veeraraghavan

Luigi Formisano

Meghana V Trivedi

Make your next move.